Opsynvi reduction of pulmonary vascular resistance demonstrated in A DUE study

US healthcare giant Johnson & Johnson (NYSE: NJ) has recently presented positive results from A DUE analyses of Opsynvi (macitentan and tadalafil), providing insight into the drug’s ability to reduce pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH).

Opsynvi has so far only been approved in Canada, but many PAH patients are already taking J&J’s Opsumit (macitentan) or United Therapeutics' (Nasdaq: UTHR) Adcirca (tadalafil).

Against this backdrop, the PAH market across the seven major markets (7MM: the USA, France, German, Italy, Spain, UK and Japan) is expected to grow at a compound annual growth rate of 5.0% to reach $7.5 billion in 2029, driven by the launch of disease-modifying therapies, drug reformulations, and increased uptake of combination therapy, forecasts analytics firm GlobalData.